
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15251A4A8AEED0B3051A4A0026E53B63.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cancer">
<meta name="citation_title" content="Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib">
<meta name="citation_author" content="Francesca Palandri">
<meta name="citation_author_institution" content="IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy">
<meta name="citation_author" content="Filippo Branzanti">
<meta name="citation_author_institution" content="Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy">
<meta name="citation_author" content="Massimiliano Bonifacio">
<meta name="citation_author_institution" content="Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy">
<meta name="citation_author" content="Elena M Elli">
<meta name="citation_author_institution" content="Divisione di Ematologia e Unità Trapianto di Midollo, IRCCS San Gerardo dei Tintori, Monza, Italy">
<meta name="citation_author" content="Erika Morsia">
<meta name="citation_author_institution" content="Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy">
<meta name="citation_author" content="Mirko Farina">
<meta name="citation_author_institution" content="Department of Clinical and Experimental Sciences, Unit of Blood Diseases and Stem Cells Transplantation, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy">
<meta name="citation_author" content="Mario Tiribelli">
<meta name="citation_author_institution" content="Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy">
<meta name="citation_author" content="Giulia Benevolo">
<meta name="citation_author_institution" content="University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy">
<meta name="citation_author" content="Eloise Beggiato">
<meta name="citation_author_institution" content="Unit of Hematology, Department of Oncology, University of Torino, Torino, Italy">
<meta name="citation_author" content="Bruno Martino">
<meta name="citation_author_institution" content="Division of Hematology, Reggio Calabria, Azienda Ospedaliera “Bianchi Melacrino Morelli”, Calabria, Italy">
<meta name="citation_author" content="Giovanni Caocci">
<meta name="citation_author_institution" content="Ematologia, Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy">
<meta name="citation_author" content="Novella Pugliese">
<meta name="citation_author_institution" content="Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy">
<meta name="citation_author" content="Alessia Tieghi">
<meta name="citation_author_institution" content="Department of Hematology, Azienda USL‐IRCCS di Reggio Emilia, Reggio Emilia, Italy">
<meta name="citation_author" content="Monica Crugnola">
<meta name="citation_author_institution" content="Haematology and BMT Centre, Azienda Ospedaliero‐Universitaria di Parma, Parma, Italy">
<meta name="citation_author" content="Gianni Binotto">
<meta name="citation_author_institution" content="Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy">
<meta name="citation_author" content="Francesco Cavazzini">
<meta name="citation_author_institution" content="Division of Hematology, University of Ferrara, Ferrara, Italy">
<meta name="citation_author" content="Elisabetta Abruzzese">
<meta name="citation_author_institution" content="Division of Hematology, Ospedale S. Eugenio, Roma, Italy">
<meta name="citation_author" content="Alessandro Isidori">
<meta name="citation_author_institution" content="Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy">
<meta name="citation_author" content="Alessandra Dedola">
<meta name="citation_author_institution" content="Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy">
<meta name="citation_author" content="Emilia Scalzulli">
<meta name="citation_author_institution" content="Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I‐Sapienza University, Rome, Italy">
<meta name="citation_author" content="Andrea Duminuco">
<meta name="citation_author_institution" content="UO Ematologia, AOU Policlinico “G. Rodolico”‐San Marco, Catania, Italy">
<meta name="citation_author" content="Luca Tosoni">
<meta name="citation_author_institution" content="Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy">
<meta name="citation_author" content="Alda Strazimiri">
<meta name="citation_author_institution" content="Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy">
<meta name="citation_author" content="Roberto M Lemoli">
<meta name="citation_author_institution" content="Department of Internal Medicine (DiMI), Clinic of Hematology, University of Genoa, Genoa, Italy">
<meta name="citation_author_institution" content="IRCCS Policlinico San Martino, Genova, Italy">
<meta name="citation_author" content="Daniela Cilloni">
<meta name="citation_author_institution" content="Department of Clinical and Biological Sciences, University of Turin, Turin, Italy">
<meta name="citation_author" content="Monica Bocchia">
<meta name="citation_author_institution" content="Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy">
<meta name="citation_author" content="Fabrizio Pane">
<meta name="citation_author_institution" content="Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy">
<meta name="citation_author" content="Chiara Sartor">
<meta name="citation_author_institution" content="IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy">
<meta name="citation_author_institution" content="Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy">
<meta name="citation_author" content="Florian H Heidel">
<meta name="citation_author_institution" content="Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany">
<meta name="citation_author" content="Massimo Breccia">
<meta name="citation_author_institution" content="Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I‐Sapienza University, Rome, Italy">
<meta name="citation_author" content="Giuseppe A Palumbo">
<meta name="citation_author_institution" content="Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy">
<meta name="citation_author" content="Andrew T Kuykendall">
<meta name="citation_author_institution" content="Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="131">
<meta name="citation_issue" content="17">
<meta name="citation_firstpage" content="e70062">
<meta name="citation_doi" content="10.1002/cncr.70062">
<meta name="citation_pmid" content="40839414">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/pdf/CNCR-131-e70062.pdf">
<meta name="description" content="The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients. To further explore this, ...">
<meta name="og:title" content="Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients. To further explore this, ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12369922">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/cncr.70062"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/CNCR-131-e70062.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369922%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12369922/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12369922/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/cncr.70062" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cancer</button></div>. 2025 Aug 21;131(17):e70062. doi: <a href="https://doi.org/10.1002/cncr.70062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/cncr.70062</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Palandri%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Francesca Palandri</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Francesca Palandri</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Palandri%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesca Palandri</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Branzanti%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Filippo Branzanti</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Filippo Branzanti</span>, <span class="degrees">MSc</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Branzanti%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Filippo Branzanti</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonifacio%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Massimiliano Bonifacio</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Massimiliano Bonifacio</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonifacio%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Massimiliano Bonifacio</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elli%20EM%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Elena M Elli</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Elena M Elli</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Divisione di Ematologia e Unità Trapianto di Midollo, IRCCS San Gerardo dei Tintori, Monza, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elli%20EM%22%5BAuthor%5D" class="usa-link"><span class="name western">Elena M Elli</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morsia%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Erika Morsia</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Erika Morsia</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morsia%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Erika Morsia</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Farina%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Mirko Farina</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Mirko Farina</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>Department of Clinical and Experimental Sciences, Unit of Blood Diseases and Stem Cells Transplantation, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Farina%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mirko Farina</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tiribelli%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Mario Tiribelli</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Mario Tiribelli</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tiribelli%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mario Tiribelli</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Benevolo%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Giulia Benevolo</span></a><div hidden="hidden" id="id8">
<h3>
<span class="name western">Giulia Benevolo</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>8</sup>
</sup>University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Benevolo%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giulia Benevolo</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Beggiato%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Eloise Beggiato</span></a><div hidden="hidden" id="id9">
<h3>
<span class="name western">Eloise Beggiato</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>9</sup>
</sup>Unit of Hematology, Department of Oncology, University of Torino, Torino, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Beggiato%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Eloise Beggiato</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martino%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Bruno Martino</span></a><div hidden="hidden" id="id10">
<h3>
<span class="name western">Bruno Martino</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>10</sup>
</sup>Division of Hematology, Reggio Calabria, Azienda Ospedaliera “Bianchi Melacrino Morelli”, Calabria, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martino%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Bruno Martino</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Caocci%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Giovanni Caocci</span></a><div hidden="hidden" id="id11">
<h3>
<span class="name western">Giovanni Caocci</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>11</sup>
</sup>Ematologia, Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Caocci%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giovanni Caocci</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pugliese%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Novella Pugliese</span></a><div hidden="hidden" id="id12">
<h3>
<span class="name western">Novella Pugliese</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>12</sup>
</sup>Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pugliese%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Novella Pugliese</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tieghi%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Alessia Tieghi</span></a><div hidden="hidden" id="id13">
<h3>
<span class="name western">Alessia Tieghi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>13</sup>
</sup>Department of Hematology, Azienda USL‐IRCCS di Reggio Emilia, Reggio Emilia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tieghi%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessia Tieghi</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Crugnola%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Monica Crugnola</span></a><div hidden="hidden" id="id14">
<h3>
<span class="name western">Monica Crugnola</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>14</sup>
</sup>Haematology and BMT Centre, Azienda Ospedaliero‐Universitaria di Parma, Parma, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Crugnola%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monica Crugnola</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Binotto%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Gianni Binotto</span></a><div hidden="hidden" id="id15">
<h3>
<span class="name western">Gianni Binotto</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>15</sup>
</sup>Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Binotto%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gianni Binotto</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cavazzini%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Francesco Cavazzini</span></a><div hidden="hidden" id="id16">
<h3>
<span class="name western">Francesco Cavazzini</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>16</sup>
</sup>Division of Hematology, University of Ferrara, Ferrara, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cavazzini%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesco Cavazzini</span></a>
</div>
</div>
<sup>16</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abruzzese%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Elisabetta Abruzzese</span></a><div hidden="hidden" id="id17">
<h3>
<span class="name western">Elisabetta Abruzzese</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>17</sup>
</sup>Division of Hematology, Ospedale S. Eugenio, Roma, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abruzzese%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elisabetta Abruzzese</span></a>
</div>
</div>
<sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Isidori%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Alessandro Isidori</span></a><div hidden="hidden" id="id18">
<h3>
<span class="name western">Alessandro Isidori</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>18</sup>
</sup>Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Isidori%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandro Isidori</span></a>
</div>
</div>
<sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dedola%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Alessandra Dedola</span></a><div hidden="hidden" id="id19">
<h3>
<span class="name western">Alessandra Dedola</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dedola%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandra Dedola</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Scalzulli%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Emilia Scalzulli</span></a><div hidden="hidden" id="id20">
<h3>
<span class="name western">Emilia Scalzulli</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>19</sup>
</sup>Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I‐Sapienza University, Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Scalzulli%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Emilia Scalzulli</span></a>
</div>
</div>
<sup>19</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Duminuco%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Andrea Duminuco</span></a><div hidden="hidden" id="id21">
<h3>
<span class="name western">Andrea Duminuco</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>20</sup>
</sup>UO Ematologia, AOU Policlinico “G. Rodolico”‐San Marco, Catania, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Duminuco%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Andrea Duminuco</span></a>
</div>
</div>
<sup>20</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tosoni%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Luca Tosoni</span></a><div hidden="hidden" id="id22">
<h3>
<span class="name western">Luca Tosoni</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tosoni%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luca Tosoni</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Strazimiri%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Alda Strazimiri</span></a><div hidden="hidden" id="id23">
<h3>
<span class="name western">Alda Strazimiri</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Strazimiri%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alda Strazimiri</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lemoli%20RM%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Roberto M Lemoli</span></a><div hidden="hidden" id="id24">
<h3>
<span class="name western">Roberto M Lemoli</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>21</sup>
</sup>Department of Internal Medicine (DiMI), Clinic of Hematology, University of Genoa, Genoa, Italy</div>
<div class="p">
<sup>
<sup>22</sup>
</sup>IRCCS Policlinico San Martino, Genova, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lemoli%20RM%22%5BAuthor%5D" class="usa-link"><span class="name western">Roberto M Lemoli</span></a>
</div>
</div>
<sup>21,</sup><sup>22</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cilloni%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id25"><span class="name western">Daniela Cilloni</span></a><div hidden="hidden" id="id25">
<h3>
<span class="name western">Daniela Cilloni</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>23</sup>
</sup>Department of Clinical and Biological Sciences, University of Turin, Turin, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cilloni%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Daniela Cilloni</span></a>
</div>
</div>
<sup>23</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bocchia%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id26"><span class="name western">Monica Bocchia</span></a><div hidden="hidden" id="id26">
<h3>
<span class="name western">Monica Bocchia</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>24</sup>
</sup>Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bocchia%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monica Bocchia</span></a>
</div>
</div>
<sup>24</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pane%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id27"><span class="name western">Fabrizio Pane</span></a><div hidden="hidden" id="id27">
<h3>
<span class="name western">Fabrizio Pane</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>12</sup>
</sup>Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pane%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fabrizio Pane</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sartor%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id28"><span class="name western">Chiara Sartor</span></a><div hidden="hidden" id="id28">
<h3>
<span class="name western">Chiara Sartor</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sartor%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chiara Sartor</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Heidel%20FH%22%5BAuthor%5D" class="usa-link" aria-describedby="id29"><span class="name western">Florian H Heidel</span></a><div hidden="hidden" id="id29">
<h3>
<span class="name western">Florian H Heidel</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>25</sup>
</sup>Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Heidel%20FH%22%5BAuthor%5D" class="usa-link"><span class="name western">Florian H Heidel</span></a>
</div>
</div>
<sup>25</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Breccia%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id30"><span class="name western">Massimo Breccia</span></a><div hidden="hidden" id="id30">
<h3>
<span class="name western">Massimo Breccia</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>19</sup>
</sup>Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I‐Sapienza University, Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Breccia%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Massimo Breccia</span></a>
</div>
</div>
<sup>19</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Palumbo%20GA%22%5BAuthor%5D" class="usa-link" aria-describedby="id31"><span class="name western">Giuseppe A Palumbo</span></a><div hidden="hidden" id="id31">
<h3>
<span class="name western">Giuseppe A Palumbo</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>26</sup>
</sup>Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Palumbo%20GA%22%5BAuthor%5D" class="usa-link"><span class="name western">Giuseppe A Palumbo</span></a>
</div>
</div>
<sup>26</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuykendall%20AT%22%5BAuthor%5D" class="usa-link" aria-describedby="id32"><span class="name western">Andrew T Kuykendall</span></a><div hidden="hidden" id="id32">
<h3>
<span class="name western">Andrew T Kuykendall</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>27</sup>
</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuykendall%20AT%22%5BAuthor%5D" class="usa-link"><span class="name western">Andrew T Kuykendall</span></a>
</div>
</div>
<sup>27,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="cncr70062-aff-0001">
<sup>
<sup>1</sup>
</sup>IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy</div>
<div id="cncr70062-aff-0002">
<sup>
<sup>2</sup>
</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy</div>
<div id="cncr70062-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy</div>
<div id="cncr70062-aff-0004">
<sup>
<sup>4</sup>
</sup>Divisione di Ematologia e Unità Trapianto di Midollo, IRCCS San Gerardo dei Tintori, Monza, Italy</div>
<div id="cncr70062-aff-0005">
<sup>
<sup>5</sup>
</sup>Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy</div>
<div id="cncr70062-aff-0006">
<sup>
<sup>6</sup>
</sup>Department of Clinical and Experimental Sciences, Unit of Blood Diseases and Stem Cells Transplantation, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy</div>
<div id="cncr70062-aff-0007">
<sup>
<sup>7</sup>
</sup>Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy</div>
<div id="cncr70062-aff-0008">
<sup>
<sup>8</sup>
</sup>University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy</div>
<div id="cncr70062-aff-0009">
<sup>
<sup>9</sup>
</sup>Unit of Hematology, Department of Oncology, University of Torino, Torino, Italy</div>
<div id="cncr70062-aff-0010">
<sup>
<sup>10</sup>
</sup>Division of Hematology, Reggio Calabria, Azienda Ospedaliera “Bianchi Melacrino Morelli”, Calabria, Italy</div>
<div id="cncr70062-aff-0011">
<sup>
<sup>11</sup>
</sup>Ematologia, Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy</div>
<div id="cncr70062-aff-0012">
<sup>
<sup>12</sup>
</sup>Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy</div>
<div id="cncr70062-aff-0013">
<sup>
<sup>13</sup>
</sup>Department of Hematology, Azienda USL‐IRCCS di Reggio Emilia, Reggio Emilia, Italy</div>
<div id="cncr70062-aff-0014">
<sup>
<sup>14</sup>
</sup>Haematology and BMT Centre, Azienda Ospedaliero‐Universitaria di Parma, Parma, Italy</div>
<div id="cncr70062-aff-0015">
<sup>
<sup>15</sup>
</sup>Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy</div>
<div id="cncr70062-aff-0016">
<sup>
<sup>16</sup>
</sup>Division of Hematology, University of Ferrara, Ferrara, Italy</div>
<div id="cncr70062-aff-0017">
<sup>
<sup>17</sup>
</sup>Division of Hematology, Ospedale S. Eugenio, Roma, Italy</div>
<div id="cncr70062-aff-0018">
<sup>
<sup>18</sup>
</sup>Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy</div>
<div id="cncr70062-aff-0019">
<sup>
<sup>19</sup>
</sup>Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I‐Sapienza University, Rome, Italy</div>
<div id="cncr70062-aff-0020">
<sup>
<sup>20</sup>
</sup>UO Ematologia, AOU Policlinico “G. Rodolico”‐San Marco, Catania, Italy</div>
<div id="cncr70062-aff-0021">
<sup>
<sup>21</sup>
</sup>Department of Internal Medicine (DiMI), Clinic of Hematology, University of Genoa, Genoa, Italy</div>
<div id="cncr70062-aff-0022">
<sup>
<sup>22</sup>
</sup>IRCCS Policlinico San Martino, Genova, Italy</div>
<div id="cncr70062-aff-0023">
<sup>
<sup>23</sup>
</sup>Department of Clinical and Biological Sciences, University of Turin, Turin, Italy</div>
<div id="cncr70062-aff-0024">
<sup>
<sup>24</sup>
</sup>Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy</div>
<div id="cncr70062-aff-0025">
<sup>
<sup>25</sup>
</sup>Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany</div>
<div id="cncr70062-aff-0026">
<sup>
<sup>26</sup>
</sup>Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy</div>
<div id="cncr70062-aff-0027">
<sup>
<sup>27</sup>
</sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence</strong>
, 
Francesca Palandri, IIRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy. 
Email: <span>francesca.palandri@unibo.it</span>
, 
Andrew T. Kuykendall, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 
Email: <span>Andrew.Kuykendall@moffitt.org</span>

</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 17; Received 2025 May 5; Accepted 2025 Jul 24; Issue date 2025 Sep 1.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Cancer</em> published by Wiley Periodicals LLC on behalf of American Cancer Society.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12369922  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40839414/" class="usa-link">40839414</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="cncr70062-sec-0001"><h3 class="pmc_sec_title">Background</h3>
<p>The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients.</p></section><section id="cncr70062-sec-0002"><h3 class="pmc_sec_title">Methods</h3>
<p>To further explore this, the authors performed a subanalysis of the “RUX‐MF” study (<a href="https://clinicaltrials.gov/ct2/show/NCT06516406" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06516406</a>) with an aim to validate the RR6 and to develop a score specific for intermediate‐1 DIPSS/MYSEC‐PM risk patients.</p></section><section id="cncr70062-sec-0003"><h3 class="pmc_sec_title">Results</h3>
<p>Among the 776 evaluable patients, 34.4%, 47.8%, and 17.8% were at low, intermediate, and high RR6 risk, with 5‐year OS of 64.1%, 51.8%, and 44.5%, respectively (<em>p</em> &lt; .001). In the 428 intermediate‐1 patients, the RR6 model did not discriminate between intermediate and low‐risk patients (5‐year OS: 74.4% vs. 72.0%, <em>p</em> = .24). The intermediate‐1 specific RR6 (iRR6) model was therefore developed by incorporating new variables: underdosed ruxolitinib with respect to platelet count at one or more time points (hazard ratio [HR], 3.91; <em>p</em> &lt; .001), absence of palpable spleen reduction by ≥50% at 6 months (HR, 1.45; <em>p</em> = .02), and red blood cell transfusion requirement at all time points (HR, 1.85; <em>p</em> = .01). The iRR6 model stratified patients into three risk categories: low (score 0, 20.3%), intermediate (score 1–2, 45.8%), and high‐risk (score &gt;2, 33.9%), with 5‐year OS of 84.8%, 76.4%, and 56.6%, respectively (<em>p</em> &lt; .0001). The iRR6 model was validated in a cohort of 95 intermediate‐1 risk patients from the Moffitt Cancer Center, yielding stratification into the same three risk categories, with 5‐year OS of 83.3% (low‐risk), 71.7% (intermediate‐risk), and 54.5% (high‐risk) (<em>p</em> = .01).</p></section><section id="cncr70062-sec-0004"><h3 class="pmc_sec_title">Conclusions</h3>
<p>The iRR6 model provides a more refined tool for the identification of intermediate‐1 MF patients who may benefit from early therapy shift.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> intermediate‐1, post‐ET myelofibrosis, post‐PV myelofibrosis, primary myelofibrosis, ruxolitinib, survival score</p></section></section><section class="abstract" id="abstract2"><h2>Short abstract</h2>
<p>The RR6 model allows for early identification of ruxolitinib‐treated myelofibrosis patients at higher risk for poorer overall survival but is less applicable to lower‐risk patients. A subanalysis of the Italian “RUX‐M” study, validated by a cohort from the Moffitt Cancer Center, led to the development of the intermediate‐1 specific RR6 (iRR6) model, which is specific for intermediate‐1 risk patients and may complement the RR6 score, offering a more granular risk stratification in patients with less advanced disease.</p></section><section id="cncr70062-sec-0010"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Myelofibrosis (MF) is a Philadelphia‐negative chronic myeloproliferative neoplasm (MPN) that can be primary (PMF) or secondary to polycythemia vera (PPV‐MF) or essential thrombocythemia (PET‐MF). It is characterized by progressive bone marrow fibrosis, splenomegaly, systemic symptoms, elevated risk of leukemic transformation, and reduced overall survival.<a href="#cncr70062-bib-0001" class="usa-link" aria-describedby="cncr70062-bib-0001">
<sup>1</sup>
</a>
</p>
<p>In MF patients presenting splenomegaly and/or symptoms, Janus kinase (<em>JAK</em>) inhibitors are the most employed first‐line therapies. Ruxolitinib was the first‐in‐class <em>JAK1/2</em> inhibitor and has been shown to improve resolution of splenomegaly and symptoms in a significant proportion of patients, thereby prolonging life.<a href="#cncr70062-bib-0002" class="usa-link" aria-describedby="cncr70062-bib-0002">
<sup>2</sup>
</a> However, approximately 50% of patients do not have a satisfactory response to ruxolitinib and approximately 50% of patients who initially respond experience disease re‐expansion over time.<a href="#cncr70062-bib-0002" class="usa-link" aria-describedby="cncr70062-bib-0002">
<sup>2</sup>
</a>
</p>
<p>Consequently, approximately 70% of patients discontinue ruxolitinib after 5 years.<a href="#cncr70062-bib-0003" class="usa-link" aria-describedby="cncr70062-bib-0003">
<sup>3</sup>
</a> In recent years, other <em>JAK2</em> inhibitors have become, or are about to become, available in clinical practice. These include fedratinib, a <em>JAK2</em>, <em>FLT3</em>, <em>BRD4</em> inhibitor that shares with ruxolitinib a discrete hematological toxicity and is effective in the control of splenomegaly in both first‐ and second‐line settings<a href="#cncr70062-bib-0004" class="usa-link" aria-describedby="cncr70062-bib-0004">
<sup>4</sup>
</a>; pacritinib, now usable in patients with severe thrombocytopenia<a href="#cncr70062-bib-0005" class="usa-link" aria-describedby="cncr70062-bib-0005">
<sup>5</sup>
</a>; and momelotinib, intended for patients with moderate to severe anemia.<a href="#cncr70062-bib-0006" class="usa-link" aria-describedby="cncr70062-bib-0006">
<sup>6</sup>
</a>, <a href="#cncr70062-bib-0007" class="usa-link" aria-describedby="cncr70062-bib-0007">
<sup>7</sup>
</a>
</p>
<p>Notwithstanding the advent of these novel therapeutic options and the multitude of ongoing clinical trials investigating drugs with disparate mechanisms of action, whether administered as monotherapy or in combination with <em>JAK2</em> inhibitors, the only truly curative therapy for MF remains allogeneic stem cell transplantation (ASCT).<a href="#cncr70062-bib-0008" class="usa-link" aria-describedby="cncr70062-bib-0008">
<sup>8</sup>
</a>
</p>
<p>ASCT is performed on patients at higher risk of early mortality due to MF. These patients are identified using a variety of prognostic models, namely the International Prognostic Scoring System (IPSS) and its dynamic variant (DIPSS/DIPSS‐plus), as well as the mutation and karyotype‐enhanced IPSS (MIPSS70 and variants) for patients with PMF<a href="#cncr70062-bib-0009" class="usa-link" aria-describedby="cncr70062-bib-0009">
<sup>9</sup>
</a>, <a href="#cncr70062-bib-0010" class="usa-link" aria-describedby="cncr70062-bib-0010">
<sup>10</sup>
</a>, <a href="#cncr70062-bib-0011" class="usa-link" aria-describedby="cncr70062-bib-0011">
<sup>11</sup>
</a>, <a href="#cncr70062-bib-0012" class="usa-link" aria-describedby="cncr70062-bib-0012">
<sup>12</sup>
</a>, <a href="#cncr70062-bib-0013" class="usa-link" aria-describedby="cncr70062-bib-0013">
<sup>13</sup>
</a>, <a href="#cncr70062-bib-0014" class="usa-link" aria-describedby="cncr70062-bib-0014">
<sup>14</sup>
</a> and the myelofibrosis secondary to PV and ET‐prognostic model (MYSEC‐PM) and for those with PPV/PET‐MF.<a href="#cncr70062-bib-0015" class="usa-link" aria-describedby="cncr70062-bib-0015">
<sup>15</sup>
</a>
</p>
<p>Identifying the optimal timing for transitioning from <em>JAK2</em> inhibitor therapy (primarily ruxolitinib) to transplantation or other alternative therapy/clinical trial remains a challenging and contentious issue in clinical practice. A delay in allogeneic transplantation in higher‐risk categories may result in a significant decline in transplant performance and patient outcomes.<a href="#cncr70062-bib-0016" class="usa-link" aria-describedby="cncr70062-bib-0016">
<sup>16</sup>
</a>
</p>
<p>A recently developed model, the response to ruxolitinib after 6 months (RR6), has been created for the early identification of ruxolitinib‐treated patients who are projected to have a reduced survival. This facilitates their early selection for a therapeutic switch, particularly in relation to the possibility of early transplantation.<a href="#cncr70062-bib-0017" class="usa-link" aria-describedby="cncr70062-bib-0017">
<sup>17</sup>
</a>
</p>
<p>Previous reports have validated the RR6 model in other MF cohorts.<a href="#cncr70062-bib-0018" class="usa-link" aria-describedby="cncr70062-bib-0018">
<sup>18</sup>
</a>, <a href="#cncr70062-bib-0019" class="usa-link" aria-describedby="cncr70062-bib-0019">
<sup>19</sup>
</a> Nevertheless, the ability to differentiate between intermediate and low risk patients was limited. Moreover, the extent to which this score can be applied to patients with intermediate‐1 risk remains unclear. Patients with intermediate‐1 risk MF are typically not considered for allogeneic stem cell transplantation and often present with less severe disease than those at higher risk, yet still experience notable splenomegaly and symptoms.<a href="#cncr70062-bib-0020" class="usa-link" aria-describedby="cncr70062-bib-0020">
<sup>20</sup>
</a>, <a href="#cncr70062-bib-0021" class="usa-link" aria-describedby="cncr70062-bib-0021">
<sup>21</sup>
</a> In these patients, ruxolitinib has demonstrated efficacy in managing symptoms and reducing splenomegaly, although a subset may exhibit suboptimal responses or disease progression, underscoring the necessity for further risk assessment models.<a href="#cncr70062-bib-0020" class="usa-link" aria-describedby="cncr70062-bib-0020">
<sup>20</sup>
</a>
</p></section><section id="cncr70062-sec-0020"><h2 class="pmc_sec_title">MATERIALS AND METHODS</h2>
<section id="cncr70062-sec-0030"><h3 class="pmc_sec_title">Patients’ population and study overview</h3>
<p>At the time of data cutoff for the current analysis (February 2024), the retrospective study “RUX‐MF” collected 1055 MF patients, treated with ruxolitinib outside clinical trials, that were used as training cohort to validate the RR6 model.</p>
<p>Inclusion criteria in this subanalysis consisted of ≥6 months of follow‐up after initiation of ruxolitinib and available information on complete blood count, red blood cell (RBC) transfusion requirements, spleen length by palpation and ruxolitinib dose at baseline, and after 3 and 6 months of ruxolitinib therapy. At initiation of ruxolitinib, all patients had platelet count &gt;50 × 10<sup>9</sup>/L and spleen palpable at ≥5 cm below the costal margin (BCM).</p>
<p>Subsequently, we focused on intermediate‐1 risk patients, to evaluate early predictors of worse overall survival in this specific population. A validation cohort comprising 95 patients with intermediate‐1 risk MF treated with ruxolitinib at the Moffitt Cancer Center (Florida) was also employed.</p></section><section id="cncr70062-sec-0040"><h3 class="pmc_sec_title">Definitions</h3>
<p>Diagnoses of PMF and PPV/PET‐MF were made according to 2016 World Health Organization criteria and International Working Group on Myelofibrosis Research and Treatment (IWG‐MRT) criteria, respectively.<a href="#cncr70062-bib-0022" class="usa-link" aria-describedby="cncr70062-bib-0022">
<sup>22</sup>
</a>, <a href="#cncr70062-bib-0023" class="usa-link" aria-describedby="cncr70062-bib-0023">
<sup>23</sup>
</a>
</p>
<p>The risk category was assessed at the time patients started on ruxolitinib according to the DIPSS or MYSEC‐PM, for primary MF and secondary MF, respectively.<a href="#cncr70062-bib-0010" class="usa-link" aria-describedby="cncr70062-bib-0010">
<sup>10</sup>
</a>, <a href="#cncr70062-bib-0015" class="usa-link" aria-describedby="cncr70062-bib-0015">
<sup>15</sup>
</a> Histologic examination was performed at local institutions; fibrosis was graded according to the European Consensus Grading System.<a href="#cncr70062-bib-0024" class="usa-link" aria-describedby="cncr70062-bib-0024">
<sup>24</sup>
</a> Unfavorable karyotype was categorized as previously described.<a href="#cncr70062-bib-0011" class="usa-link" aria-describedby="cncr70062-bib-0011">
<sup>11</sup>
</a> High molecular risk (HMR) pathogenetic mutations were defined as those including <em>ASXL1</em>, <em>SRSF2</em>, <em>EZH2</em>, <em>IDH1</em>, and <em>IDH2</em>, <em>U2AF1</em>.<a href="#cncr70062-bib-0012" class="usa-link" aria-describedby="cncr70062-bib-0012">
<sup>12</sup>
</a> Anemia was defined according to Common Terminology Criteria for Adverse Events.<a href="#cncr70062-bib-0025" class="usa-link" aria-describedby="cncr70062-bib-0025">
<sup>25</sup>
</a>
</p>
<p>MF‐related symptoms were assessed using the 10‐item Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN10‐TSS).<a href="#cncr70062-bib-0026" class="usa-link" aria-describedby="cncr70062-bib-0026">
<sup>26</sup>
</a> Spleen and symptoms responses were routinely assessed by palpation and by periodical total symptom score (TSS) evaluation, according to 2013 IWG‐MRT criteria.<a href="#cncr70062-bib-0023" class="usa-link" aria-describedby="cncr70062-bib-0023">
<sup>23</sup>
</a>
</p></section><section id="cncr70062-sec-0050"><h3 class="pmc_sec_title">Ethical aspects</h3>
<p>The RUX‐MF study (<a href="https://clinicaltrials.gov/ct2/show/NCT06516406" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06516406</a>) was performed in accordance with the guidelines of the institutional review boards of the participating centers and the standards of the Helsinki Declaration. The promoter of this study was the IRCCS Azienda Ospedaliero‐Universitaria S. Orsola‐Malpighi, Bologna, which obtained approval from the Area Vasta Emilia Centro Ethics Committee (approval file number: 048/2022/Oss/AOUBo). The study was approved by the local ethics committee of participating centers (protocol code: RUX‐MF) and has no commercial support.</p></section><section id="cncr70062-sec-0060"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>Continuous variables are expressed as medians and ranges or means and standard deviations, whereas categorical variables are presented as frequencies and percentages. We used the Wilcoxon‐Mann‐Whitney rank‐sum test or the <em>t</em>‐test for comparisons between groups, and associations between categorical variables (2‐way tables) were tested using the Fisher exact test or the χ<sup>2</sup> test, as appropriate.</p>
<p>Prognostic factors for survival in intermediate‐1 patients were identified using univariate and multivariable Cox proportional hazards model. Multivariable Cox analysis was conducted on variables with <em>p</em> values &lt;0.05 at univariate analysis, to assess hazard ratio (HR). To avoid the issue of multicollinearity and to remove highly correlated predictors from the model, collinearity among variables was detected using the Pearson correlation test. Variables that were associated with other factors in univariate analysis were excluded from the multivariable analysis. The following variables were assessed: (1) hemoglobin (Hb) decrease between 6 months and baseline, adjusted for baseline transfusions; (2) acquisition of leukocytosis, defined as white blood cells (WBC) &gt;25 × 10<sup>9</sup>/L at 6 months in subjects with WBC ≤25 × 10<sup>9</sup>/L at baseline; (3) worsening thrombocytopenia, considering the following platelet (PLT) count categories: ≥200 × 10<sup>9</sup>/L, 100 to 199 × 10<sup>9</sup>/L, 75 to 99 × 10<sup>9</sup>/L, 50 to 74 × 10<sup>9</sup>/L, and &lt;50 × 10<sup>9</sup>/L between 6 months and baseline; (4) underdosed ruxolitinib as a categorical variable, considering individuals “treated with ruxolitinib underdosed according to prescribing indication based on PLT count” versus those “treated with correct prescribing dose at all time points (baseline, 3 months, and/or 6 months)”; (5) reduction by ≤50% of palpable spleen length at 6 months (SR50), including no SR50 at months 3 and 6 and no SR50 at month 6, after SR50 at month 3; and (6) RBC transfusion requirement, considering the following categories “RBC transfusions at two time points,” and “RBC transfusions at all time points (baseline, 3 months, and 6 months).”</p>
<p>These variables were selected based on their mechanistic relevance to disease biology and treatment response in ruxolitinib‐treated MF patients. In particular, changes in hemoglobin, leukocyte, and platelet counts over time were evaluated as indicators of disease evolution or therapy‐related cytopenias. The requirement for RBC transfusion was included as a marker for persistent anemia and bone marrow dysfunction, both of which are known to have an adverse impact on prognosis.<a href="#cncr70062-bib-0027" class="usa-link" aria-describedby="cncr70062-bib-0027">
<sup>27</sup>
</a> Underdosing of ruxolitinib relative to platelet count was tested in place of absolute dosing, to account for treatment intensity normalized to patient‐specific hematologic tolerance. This definition reflects adherence to the approved prescribing information and is more consistent with previous data showing that ruxolitinib underdosing may impact treatment outcomes.<a href="#cncr70062-bib-0028" class="usa-link" aria-describedby="cncr70062-bib-0028">
<sup>28</sup>
</a> Finally, spleen response was assessed using a stricter cutoff (≥50% reduction by palpation), which was hypothesized to better reflect meaningful disease control in intermediate‐1 risk patients, who are more likely to achieve spleen shrinkage than high‐risk individuals. All variables were selected a priori based on clinical plausibility and were uniformly available across the study population.</p>
<p>Survival analysis comparing risk categories were performed using Kaplan–Meier curves, and differences were evaluated using log‐rank test. Overall survival (OS) was calculated from the date of ruxolitinib start, to either death, last contact, or ASCT.</p>
<p>Tests were two‐sided, and <em>p</em> values &lt;.05 were considered significant. Analyses were performed using STATA/SE software version 18.0 (StataCorp).</p></section></section><section id="cncr70062-sec-0070"><h2 class="pmc_sec_title">RESULTS</h2>
<section id="cncr70062-sec-0080"><h3 class="pmc_sec_title">Baseline characteristics of the entire cohort</h3>
<p>The study included 776 patients from the RUX‐MF study cohort who met the inclusion criteria; 279 (36.0%) patients were excluded due to absence of palpable splenomegaly at baseline, ruxolitinib duration &lt;6 months, or missing values required for RR6 validation (Figure <a href="#cncr70062-sup-0001" class="usa-link">S1</a>)</p></section><section id="cncr70062-sec-0090"><h3 class="pmc_sec_title">Overall cohort characteristics are summed up in Table <a href="#cncr70062-tbl-0001" class="usa-link">1</a>
</h3>
<section class="tw xbox font-sm" id="cncr70062-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Patient’s characteristics at RUX start.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Total cohort (<em>n</em> = 776)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Intermediate‐1 (<em>n</em> = 428)</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age, years, median (range)</td>
<td align="left" valign="top" rowspan="1" colspan="1">68.1 (24.7–92.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">65.0 (24.7–88.2)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age &gt;65 years, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">485 (62.5)</td>
<td align="left" valign="top" rowspan="1" colspan="1">217 (50.7)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Male sex, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">448 (57.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">244 (57.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Primary MF, No. (%) </td>
<td align="left" valign="top" rowspan="1" colspan="1">397 (51.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">213 (49.8)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Post‐PV MF</td>
<td align="left" valign="top" rowspan="1" colspan="1">216 (27.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">135 (31.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Post‐ET MF</td>
<td align="left" valign="top" rowspan="1" colspan="1">163 (21.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">80 (18.7)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Driver mutation, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>JAK2</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">593 (76.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">338 (79.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>CALR</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">96 (12.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">52 (12.1)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>MPL</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">17 (2.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">7 (1.6)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Triple negative</td>
<td align="left" valign="top" rowspan="1" colspan="1">40 (5.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">17 (4.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not available</td>
<td align="left" valign="top" rowspan="1" colspan="1">30 (3.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (3.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">RUX starting daily dose, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">10–20 mg</td>
<td align="left" valign="top" rowspan="1" colspan="1">282 (36.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">188 (43.9)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">30–40 mg</td>
<td align="left" valign="top" rowspan="1" colspan="1">494 (63.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">240 (56.1)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">DIPSS or MYSEC‐PM score, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">INT‐1</td>
<td align="left" valign="top" rowspan="1" colspan="1">428 (55.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">428 (100.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">INT‐2/HIGH</td>
<td align="left" valign="top" rowspan="1" colspan="1">348 (44.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">HMR mutation, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">101/197 (51.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">60/122 (49.2)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Hemoglobin, g/dL, median (range)</td>
<td align="left" valign="top" rowspan="1" colspan="1">11.2 (5.0–18.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12.1 (6.9–18.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hemoglobin &lt;10 g/dL, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">272 (35.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">24 (5.6)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">RBC transfusions requirement, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">132 (17.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">17 (4.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Platelet count, ×10<sup>9</sup>/L, median (range)</td>
<td align="left" valign="top" rowspan="1" colspan="1">265 (56–1887)</td>
<td align="left" valign="top" rowspan="1" colspan="1">283 (56–1632)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Platelet count &lt;100 ×10<sup>9</sup>/L, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">68 (8.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">32 (7.5)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">White blood cell count, ×10<sup>9</sup>/L, median (range)</td>
<td align="left" valign="top" rowspan="1" colspan="1">11.7 (1.1–155.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">11.3 (1.1–78.9)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White blood cell count &gt;25 ×10<sup>9</sup>/L, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">119 (15.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">36 (8.4)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Peripheral blast count, mean ± SD</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.97 ± 1.61</td>
<td align="left" valign="top" rowspan="1" colspan="1">113/417 (27.1%)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Blasts ≥1%, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">141/557 (25.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">113 (26.4)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Spleen length BCM, median (range), cm</td>
<td align="left" valign="top" rowspan="1" colspan="1">11 (5–35)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10 (5–35)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Spleen length BCM ≥10 cm, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">387 (49.9)</td>
<td align="left" valign="top" rowspan="1" colspan="1">198 (46.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total symptoms score, median (range)</td>
<td align="left" valign="top" rowspan="1" colspan="1">20 (0–100)</td>
<td align="left" valign="top" rowspan="1" colspan="1">20 (0–100)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total symptoms score ≥20, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">450 (58.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">223 (52.1)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Constitutional symptoms, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">574 (74.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">143 (33.4)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70062-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="cncr70062-note-0001"><p>Abbreviations: BCM, below costal margin; DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; HMR, high molecular risk; INT, intermediate; MF, myelofibrosis; MYSEC‐PM, myelofibrosis secondary to PV and ET‐prognostic model; PV, polycythemia vera; RBC, red blood cells; RUX, ruxolitinib.</p></div></div></section><p>At the start of ruxolitinib, 55.2% of the patients were at intermediate‐1 risk. The median baseline hemoglobin level was 11.2 g/dL, with 132 (17.0%) patients having RBC transfusion requirement. The median platelet count was 265 × 10<sup>9</sup>/L (range: 56–1887), and 49.9% of the patients had splenomegaly palpable at ≥10 cm below the costal margin. Additionally, 58.0% of patients were highly symptomatic, with a TSS ≥20.</p></section><section id="cncr70062-sec-0100"><h3 class="pmc_sec_title">Distribution of variables and validation of the RR6 in the entire cohort</h3>
<p>The distribution of the RR6 variables was as follows: 33.4% of the patients received a ruxolitinib dose &lt;20 mg twice daily at baseline, a proportion that increased to 64.2% at 3 months and 74.6% at 6 months. RBC transfusion requirement was recorded in 17% of patients at baseline, increasing to 34% at 3 months and remaining stable at 32.6% at 6 months. Approximately one‐third (31.7%) of patients failed to achieve a spleen reduction by at least 30% compared to baseline (SR30) at 3 months, with 37.6% not achieving SR30 at 6 months.</p>
<p>The RR6 model was first applied to the entire cohort. The RR6 model stratified patients into three risk groups: low‐risk (score 0, <em>n</em> = 267, 34.4%), intermediate‐risk (score 1–2, <em>n</em> = 371, 47.8%), and high‐risk (score &gt;2, <em>n</em> = 138, 17.8%). The 5‐year OS rates were 64.1% for low‐risk patients, 51.8% for intermediate‐risk patients, and 44.5% for high‐risk patients (<em>p</em> &lt; .0001), with statistically significant differences across all the risk categories (low vs. intermediate, <em>p</em> = .003; intermediate vs. high, <em>p</em> = .02; low vs. high, <em>p</em> = .0001) (Figure <a href="#cncr70062-fig-0001" class="usa-link">1</a>).</p>
<figure class="fig xbox font-sm" id="cncr70062-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf66/12369922/89093f9387a4/CNCR-131-e70062-g002.jpg" loading="lazy" id="jats-graphic-1" height="476" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70062-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>RR6 validation in the overall cohort. INT indicates intermediate; RR6, response to ruxolitinib after 6 months; RUX, ruxolitinib.</p></figcaption></figure></section><section id="cncr70062-sec-0110"><h3 class="pmc_sec_title">Characteristics of the intermediate‐1 cohort</h3>
<p>Of the total cohort, 428 patients were classified as intermediate‐1 risk according to DIPSS or MYSEC‐PM at ruxolitinib start (Table <a href="#cncr70062-tbl-0001" class="usa-link">1</a>).</p>
<p>The distribution of the RR6 variables within the intermediate‐1 cohort was found to be consistent with that observed in the entire cohort: 57.0% of patients were receiving a ruxolitinib dose &lt;20 mg twice daily at baseline, increasing to 69.4% at 3 months and 71.5% at 6 months. RBC transfusion requirement was recorded in 4.2% of patients at baseline, increasing sharply to 16.7% at 3 months, and 15.7% at 6 months. Approximately 41.4% of patients failed to achieve SR30 at 3 months, with 33.1% not reaching SR30 at 6 months (Table <a href="#cncr70062-sup-0001" class="usa-link">S1</a>).</p></section><section id="cncr70062-sec-0120"><h3 class="pmc_sec_title">Application of the RR6 model to the intermediate‐1 cohort</h3>
<p>In univariate analysis, RBC transfusion requirements at all time points (HR, 2.65 [95% confidence interval (CI), 1.30–5.40], <em>p</em> = .007) and RBC transfusion requirement at 3 and 6 months (HR, 1.55 [95% CI, 1.10–2.17], <em>p</em> = 0.011) were significantly associated with a worse OS, whereas ruxolitinib dose &lt;20 twice daily (HR, 1.22 [95% CI, 0.73–1.44], <em>p</em> = .50) and failure to achieve SR30 at 3 and/or 6 months (HR, 1.35 [95% CI, 0.90–1.52], <em>p</em> = .08), did not correlate with a worse prognosis. In multivariate analysis, only RBC transfusion requirement at all time points remained significantly associated with OS (HR, 2.10 [95% CI, 1.10–4.40], <em>p</em> = .05). Ruxolitinib dose &lt;20 mg twice daily at all time points (HR, 1.10 [95% CI, 0.80–1.52], <em>p</em> = .49) and failure to achieve SR30 at 3 and/or 6 months (HR, 1.42 [95% CI, 0.98–1.99], <em>p</em> = .06) did not show significant predictive value for survival in this specific cohort (Figure <a href="#cncr70062-sup-0001" class="usa-link">S2</a>).</p>
<p>When the RR6 model was applied to the intermediate‐1 cohort, the 5‐year OS was 74.4% in the low‐risk group (<em>n</em> = 121, 28.3%) and 72.0% in the intermediate‐risk group (<em>n</em> = 223, 52.1%), indicating no significant difference between the two categories (<em>p</em> = .24). However, the high‐risk group (<em>n</em> = 84, 19.6%) showed a significantly poorer 5‐year OS of 57.4% (vs. low‐risk, <em>p</em> = .004; vs. intermediate‐risk, <em>p</em> = .009) (Figure <a href="#cncr70062-fig-0002" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="cncr70062-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf66/12369922/58678bf27178/CNCR-131-e70062-g004.jpg" loading="lazy" id="jats-graphic-3" height="474" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70062-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>RR6 validation in intermediate‐1 risk patients. INT indicates intermediate; RR6, response to ruxolitinib after 6 months; RUX, ruxolitinib.</p></figcaption></figure></section><section id="cncr70062-sec-0130"><h3 class="pmc_sec_title">Development of the intermediate‐1 RR6 score</h3>
<section id="cncr70062-sec-0140"><h4 class="pmc_sec_title">Testing new variables</h4>
<p>New variables were tested in both univariate and multivariable analyses to improve risk stratification in intermediate‐1 patients (Figure <a href="#cncr70062-fig-0003" class="usa-link">3</a>). The following factors were found to be significant in multivariate analysis: underdosed ruxolitinib at any time point (HR, 3.91 [95% CI, 2.61–5.85], <em>p</em> &lt; .001); absence of SR50 at 6 months (HR, 1.45 [95% CI, 1.06–1.99], <em>p</em> = .02); RBC transfusion requirement at all time points (HR, 1.85 [95% CI, 1.16–2.94], <em>p</em> = 0.01). RBC transfusion requirement at two time points was significant just in univariate analysis (univariate: HR, 2.13 [95% CI, 1.05–4.36], <em>p</em> = 0.05; multivariate: HR, 1.74 [95% CI, 0.84–3.59], <em>p</em> = 0.14).</p>
<figure class="fig xbox font-sm" id="cncr70062-fig-0003"><h5 class="obj_head">FIGURE 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf66/12369922/106e769f8a63/CNCR-131-e70062-g003.jpg" loading="lazy" id="jats-graphic-5" height="302" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70062-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Variables associated with overall survival in the intermediate‐1 risk cohort. CI indicates confidence interval; Hb, hemoglobin; HR, hazard ratio; RBC, red blood cells; RUX, ruxolitinib; WBC, white blood cells.</p></figcaption></figure><p>Based on these findings, the intermediate‐1 RR6 (iRR6) model was developed, with the following point assignment: 2 points for underdosed ruxolitinib at any time points; 1.5 points for absence of SR50 at 6 months and for RBC transfusion requirement at all time points; and 1 point for RBC transfusion requirement at two time points.</p>
<p>The distribution of these variables in the intermediate‐1 cohort showed that: 40.0% received underdosed ruxolitinib at baseline, increasing at 45.6% and 41.8% of patients at 3 and 6 months respectively; 52.1% failed to achieve SR50 at 6 months; 18.7% required RBC transfusions at two time points, and 15.7% required transfusions at all time points (Table <a href="#cncr70062-sup-0001" class="usa-link">S1</a>).</p></section></section><section id="cncr70062-sec-0150"><h3 class="pmc_sec_title">Application of the iRR6 model in the RUX‐MF cohort</h3>
<p>The iRR6 model was then applied to the intermediate‐1 cohort, effectively stratifying patients into three risk groups: low‐risk (score 0): 20.3% (<em>n =</em> 87) of patients with a 5‐year OS of 84.8% (median OS: not reached); intermediate‐risk (score 1–2): 45.8% (<em>n =</em> 196) of patients with a 5‐year OS of 76.4% (median OS: 9.24 years; 95% CI, 6.63–not reached); high‐risk (score &gt;2): 33.9% of patients with a 5‐year OS of 56.6% (median OS: 5.77 years; 95% CI, 4.80–6.29) (<em>p</em> &lt; .0001) (Figure <a href="#cncr70062-fig-0004" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="cncr70062-fig-0004"><h4 class="obj_head">FIGURE 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf66/12369922/5051e86d0ba0/CNCR-131-e70062-g001.jpg" loading="lazy" id="jats-graphic-7" height="480" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70062-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>iRR6 model. INT indicates intermediate; iRR6, intermediate‐1 specific response to ruxolitinib after 6 months; RUX, ruxolitinib.</p></figcaption></figure><p>To evaluate its performance across distinct prognostic classifications, we also applied the iRR6 model separately to PMF and SMF patients. In both the intermediate‐1 DIPSS‐defined PMF cohort and the MYSEC‐PM‐defined SMF cohort, the iRR6 model consistently identified three prognostic categories with significantly different overall survival (PMF: low‐risk, median OS: not reached; intermediate‐risk, median OS: 9.25 years; 95% CI, 5.93–not reached; high‐risk, median OS: 4.66 years; 95% CI, 3.42–5.77, <em>p</em> &lt; .0001; SMF: low‐risk, median OS: not reached; intermediate‐risk: 9.58 years; 95% CI, 6.64–not reached; high‐risk, median OS: 6.29 years; 95% CI, 5.47–7.27, <em>p</em> &lt; .0001) (Figure <a href="#cncr70062-sup-0001" class="usa-link">S3)</a>.</p></section><section id="cncr70062-sec-0160"><h3 class="pmc_sec_title">Validation of the iRR6 model in the Moffitt Cancer Center cohort</h3>
<p>To validate the iRR6 model, it was tested on a separate cohort of 95 intermediate‐1 patients from the Moffitt Cancer Center. The median age of this cohort was 63.4 years (range: 25.1–87.3) and 55.8% were male. Their baseline characteristics were comparable to those of the RUX‐MF cohort (Table <a href="#cncr70062-sup-0001" class="usa-link">S2</a>).</p>
<p>The distribution of iRR6 variables in the Moffitt cohort was similar to the RUX‐MF cohort: 53.7% of patients received ruxolitinib underdosed at baseline, falling to 41.1% and 37.9% at 3 and 6 months, respectively; 55.8% failed to achieve SR50 at 6 months; 17.9% needed transfusion requirement at two time points, and 5.3% at all time points (Table <a href="#cncr70062-sup-0001" class="usa-link">S1)</a>.</p>
<p>The iRR6 model was successfully applied to the Moffitt cohort, yielding significant stratification into the same three risk groups: low‐risk: 16.8% (<em>n</em> = 16) of patients with a 5‐year OS of 83.3%; intermediate‐risk: 34.7% of patients (<em>n</em> = 33) with a 5‐year OS of 71.7%; high‐risk: 48.4% of patients (<em>n</em> = 46) with a 5‐year OS of 54.5% (<em>p</em> = .01) (Figure <a href="#cncr70062-sup-0001" class="usa-link">S4</a>).</p></section></section><section id="cncr70062-sec-0170"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p>The primary result of the present study is the validation of the RR6 model. In contrast to previous validations, in which intermediate and low‐risk patients exhibited nonsignificantly different survival rates, our cohort demonstrated that the RR6 effectively distinguished three categories with distinct survival expectations. This was likely attributable to the substantial patient sample size, which may have counterbalanced the inherent limitations of retrospective data collection.</p>
<p>The RR6 model was primarily developed to inform early therapeutic decisions in MF patients undergoing ruxolitinib treatment, with a specific focus on avoiding delays that could potentially compromise transplant outcomes. However, it was developed in a mixed cohort of higher‐risk patients, who are generally evaluated for transplantation, and intermediate‐1 risk patients, whose clinical presentation and treatment trajectory is heterogeneous.<a href="#cncr70062-bib-0029" class="usa-link" aria-describedby="cncr70062-bib-0029">
<sup>29</sup>
</a>
</p>
<p>Optimal treatment of intermediate‐1 risk patients is a challenge. They, historically, were not included in the COMFORT studies and yet, they benefit from ruxolitinib therapy with higher‐response rates, less cytopenias, and lower discontinuation rates.<a href="#cncr70062-bib-0020" class="usa-link" aria-describedby="cncr70062-bib-0020">
<sup>20</sup>
</a>, <a href="#cncr70062-bib-0030" class="usa-link" aria-describedby="cncr70062-bib-0030">
<sup>30</sup>
</a> Furthermore, they constitute the majority of MF patients receiving ruxolitinib in a real‐life context. Finally, they are frequently not considered for transplantation, despite being younger patients who could potentially benefit more from the procedure. Therefore, it is crucial to identify the subset of intermediate‐1 risk patients who are unlikely to respond well so that we can optimize their therapy (or otherwise refer them for transplantation). In this study, we observed that the RR6 model, when applied specifically to intermediate‐1 patients, failed to distinguish between low‐ and intermediate‐risk patients. This highlights the need for more refined prognostic tools in this setting.<a href="#cncr70062-bib-0020" class="usa-link" aria-describedby="cncr70062-bib-0020">
<sup>20</sup>
</a>, <a href="#cncr70062-bib-0021" class="usa-link" aria-describedby="cncr70062-bib-0021">
<sup>21</sup>
</a>
</p>
<p>Failure to achieve an SR30 did not maintain a prognostic value in intermediate‐1 risk patients, who are instead better stratified using a more significant response cutoff (SR50). This confirms the better performance of ruxolitinib when used early in the disease course.<a href="#cncr70062-bib-0031" class="usa-link" aria-describedby="cncr70062-bib-0031">
<sup>31</sup>
</a>, <a href="#cncr70062-bib-0032" class="usa-link" aria-describedby="cncr70062-bib-0032">
<sup>32</sup>
</a>, <a href="#cncr70062-bib-0033" class="usa-link" aria-describedby="cncr70062-bib-0033">
<sup>33</sup>
</a> Moreover, the nonuse of ruxolitinib maximum doses, which are often reserved for intermediate‐1 risk patients, was not significantly associated with survival. In contrast, failure to dose adequately with respect to platelet count confirmed a significant prognostic impact. Underdosing of ruxolitinib, often due to concerns over anemia, has been reported in previous studies in a substantial fraction of patients.<a href="#cncr70062-bib-0034" class="usa-link" aria-describedby="cncr70062-bib-0034">
<sup>34</sup>
</a> Notably, the underdosing of ruxolitinib was associated not only with reduced response rates but also with poorer survival outcomes.<a href="#cncr70062-bib-0035" class="usa-link" aria-describedby="cncr70062-bib-0035">
<sup>35</sup>
</a> Overall, these results underscore the significance of maintaining optimal dosing to ensure the greatest therapeutic effect and most favorable patient outcomes, particularly for intermediate‐1 risk patients, who could benefit most from this dosing strategy, with lesser toxicity.<a href="#cncr70062-bib-0036" class="usa-link" aria-describedby="cncr70062-bib-0036">
<sup>36</sup>
</a>, <a href="#cncr70062-bib-0037" class="usa-link" aria-describedby="cncr70062-bib-0037">
<sup>37</sup>
</a>, <a href="#cncr70062-bib-0038" class="usa-link" aria-describedby="cncr70062-bib-0038">
<sup>38</sup>
</a>, <a href="#cncr70062-bib-0039" class="usa-link" aria-describedby="cncr70062-bib-0039">
<sup>39</sup>
</a>
</p>
<p>The limitations of this study are acknowledged, including its retrospective nature, the suboptimal reliability of palpation for the assessment of spleen response, and the lack of information on patient adherence to ruxolitinib. Another limitation of this study is the incomplete availability of molecular data. As the RUX‐MF registry included patients treated from 2013 onward, next‐generation sequencing was not systematically implemented in clinical workflows at that time and was performed in only a subset of cases. Therefore, risk stratification at baseline was conducted using DIPSS or MYSEC‐PM, in alignment with real‐world clinical practice. Although we acknowledge that current prognostic models increasingly incorporate molecular features, our analysis focused on dynamic projection after 6 months of therapy, aiming to identify early indicators of long‐term outcome in intermediate‐1 risk patients. Prospective studies with comprehensive genomic profiling may further enhance the integration between molecular and treatment‐based risk models.</p>
<p>Despite these limitations, the validation of the iRR6 model in an independent cohort from the Moffitt Cancer Center lends further support to the generalizability and reliability of the model. Furthermore, a high degree of similarity was observed in the distribution of iRR6 variables between the Moffitt cohort and the original RUX‐MF cohort, suggesting that the iRR6 model can be applied broadly to intermediate‐1 patients treated with ruxolitinib, regardless of geographic or institutional disparities.</p>
<p>The iRR6 score does not contradict the original RR6 model but rather integrates it. The RR6 score continues to serve as a valuable tool for identifying patients who are likely to experience poorer outcomes during ruxolitinib therapy and its use in clinical practice must be encouraged. The iRR6 score has been developed to complement it, offering a more granular risk stratification in patients with less advanced disease, with the potential to mitigate the risks associated with prolonged ineffective therapies and delayed transitions to alternative treatments in this setting.</p>
<p>Further investigation is required to determine whether and which early interventions may ultimately improve outcomes. This should be the subject of future studies.</p></section><section id="cncr70062-sec-0180"><h2 class="pmc_sec_title">AUTHOR CONTRIBUTIONS</h2>
<p>
<strong>Francesca Palandri</strong>: Conceptualization, investigation, funding acquisition, writing–original draft, writing–review and editing, data curation, resources, and visualization. <strong>Filippo Branzanti</strong>: Conceptualization, writing–original draft, writing–review and editing, data curation, formal analysis, and visualization. <strong>Massimiliano Bonifacio</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources. <strong>Elena M. Elli</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources. <strong>Erika Morsia</strong>: Conceptualization, investigation, visualization, writing–review and editing, resources. <strong>Mirko Farina</strong>: Conceptualization, investigation, visualization, resources, and writing–review and editing. <strong>Mario Tiribelli</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources. <strong>Giulia Benevolo</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources. <strong>Eloise Beggiato</strong>: Investigation, writing–review and editing, and resources. <strong>Bruno Martino</strong>: Investigation, writing–review and editing, and resources. <strong>Giovanni Caocci</strong>: Investigation, writing–review and editing, and resources. <strong>Novella Pugliese</strong>: Investigation, writing–review and editing, and resources. <strong>Alessia Tieghi</strong>: Investigation, writing–review and editing, and resources. <strong>Monica Crugnola</strong>: Investigation, writing–review and editing, and resources. <strong>Gianni Binotto</strong>: Investigation, writing–review and editing, and resources. <strong>Francesco Cavazzini</strong>: Investigation, writing–review and editing, and resources. <strong>Elisabetta Abruzzese</strong>: Investigation, writing–review and editing, and resources. <strong>Alessandro Isidori</strong>: Investigation, writing–review and editing, and resources. <strong>Alessandra Dedola</strong>: Conceptualization, Investigation, visualization, writing–review and editing, and resources. <strong>Emilia Scalzulli</strong>: Investigation, writing–review and editing, and resources. <strong>Andrea Duminuco</strong>: Investigation, writing–review and editing, and resources. <strong>Luca Tosoni</strong>: Investigation, writing–review and editing, and resources. <strong>Alda Strazimiri</strong>: Investigation, writing–review and editing, and resources. <strong>Roberto M. Lemoli</strong>: Investigation, writing–review and editing, and resources. <strong>Daniela Cilloni</strong>: Investigation, writing–review and editing, and resources. <strong>Monica Bocchia</strong>: Investigation, writing–review and editing, and resources. <strong>Fabrizio Pane</strong>: Investigation, writing–review and editing, and resources. <strong>Chiara Sartor</strong>: Investigation, writing–review and editing, and resources. <strong>Florian H. Heidel</strong>: Visualization, Writing–review and editing. <strong>Massimo Breccia</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources. <strong>Giuseppe A. Palumbo</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources. <strong>Andrew T. Kuykendall</strong>: Conceptualization, investigation, visualization, writing–review and editing, and resources.</p></section><section id="cncr70062-sec-0200"><h2 class="pmc_sec_title">CONFLICT OF INTEREST STATEMENT</h2>
<p>Elisabetta Abruzzese reports consulting fees from Ascentage Pharma, Bristol‐Myers Squibb, GlaxoSmithKline, Incyte, Instituto Científico Pfizer, and Novartis. Giulia Benevolo reports consulting fees from Bristol‐Myers Squibb and GlaxoSmithKline; fees for professional activities from AOP Health; and honoraria from Novartis, Janssen, Amgen, and Takeda. Gianni Binotto reports honoraria from Novartis, Incyte, Bristol‐Myers Squibb‐Celgene, and Pfizer. Monica Bocchia reports consulting fees from Incyte and Novartis; and travel fees from BeiGene USA, Inc. Massimo Breccia reports honoraria from Novartis, Bristol‐Myers Squibb, Pfizer, and Incyte. Monica Crugnola reports honoraria from Novartis and Amgen. Andrea Duminuco reports consulting fees from A.O.U. Policlinico “G. Rodolico‐San Marco.” Florian H. Heidel reports consulting fees from AbbVie, AOP Orphan Pharmaceuticals, Bristol‐Myers Squibb, CTI Biopharma, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Novartis, Prelude Therapeutics, and Silence Pharmaceuticals. Andrew T. Kuykendall has received honorarium and/or consulting fees from Incyte, Protagonist, Kartos Therapeutics, PharmaEssentia, AbbVie, Imago Biosciences, Karyopharm Therapeutics Inc, PharmaEssentia, Blueprint Medicines Corporation, Constellation, CTI Biopharma, Novartis, and Sierra Oncology; and grant and/or contract funding from Protagonist Therapeutics, Inc, Bristol‐Myers Squibb, Constellation, Geron Corporation, Janssen Pharmaceuticals, Novartis, and Sierra Oncology. Roberto M. Lemoli reports honoraria from Jazz, Pfizer, AbbVie, Bristol‐Myers Squibb, Sanofi, and StemLine. Francesca Palandri participated in the speakers bureau and advisory board of Novartis, Bristol‐Myers Squibb, AOP Health, Sierra Oncology, Incyte, Telios, AbbVie, Constellation‐Morphosys, Sobi and GlaxoSmithKline, Sanofi, and Takeda Oncology. Giuseppe A. Palumbo reports consultancy and honoraria from AbbVie, AOP, AstraZeneca, Bristol‐Myers Squibb, Incyte, GlaxoSmithKline, Morphosys, and Novartis; and travel fees from AbbVie, AstraZeneca, BeiGene, Ltd, Janssen Biotech, Sobi, and Stemline Therapeutics Inc. Fabrizio Pane reports honoraria from Incyte, Novartis, Jazz, Bristol‐Myers Squibb‐Celgene, Amgen, and Gilead. Mario Tiribelli reports honoraria from and has served on speakers’ bureaus for Novartis, Bristol‐Myers Squibb, Pfizer, and Incyte. Massimiliano Bonifacio reports honoraria from Novartis, Bristol‐Myers Squibb, Pfizer, and Incyte, Amgen, Ascentage Pharma, Blueprint Medicines, Clinigen, and Glaxo‐Smith Kline. The other authors declare no conflicts of interest.</p></section><section id="sec24"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="cncr70062-sup-0001"><div class="caption p"><p>Supplementary Material</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12369922/bin/CNCR-131-e70062-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">CNCR-131-e70062-s001.docx</a><sup> (670.1KB, docx) </sup>
</div></div></section></section><section id="cncr70062-sec-0190" class="ack"><h2 class="pmc_sec_title">ACKNOWLEDGMENTS</h2>
<p>This work was supported by Ministero della Salute Ricerca corrente and by BolognAIL. The work reported in this publication was funded by Italian Ministry of Health (RC‐2024‐2790083 project).</p></section><section id="notes1"><p>

Palandri F, Branzanti F, Bonifacio M, et al. Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib. Cancer. 2025;e70062. doi: 10.1002/cncr.70062

</p></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Francesca Palandri, Email: francesca.palandri@unibo.it.</p>
<p>Andrew T. Kuykendall, Email: Andrew.Kuykendall@moffitt.org.</p></section><section id="cncr70062-sec-0220"><h2 class="pmc_sec_title">DATA AVAILABILITY STATEMENT</h2>
<p>The data that support the findings of this study are available from the corresponding author on reasonable request to the corresponding author (<span>francesca.palandri@unibo.it</span>) at the following <a href="https://zenodo.org/records/14017637" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://zenodo.org/records/14017637</a>.</p></section><section id="cncr70062-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="cncr70062-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="cncr70062-bib-0001">
<span class="label">1.</span><cite>
Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954‐1970. doi: 10.1182/BLOOD.2022017423

</cite> [<a href="https://doi.org/10.1182/BLOOD.2022017423" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10646775/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36416738/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Myelofibrosis&amp;author=F%20Passamonti&amp;author=B%20Mora&amp;volume=141&amp;issue=16&amp;publication_year=2023&amp;pages=1954-1970&amp;pmid=36416738&amp;doi=10.1182/BLOOD.2022017423&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0002">
<span class="label">2.</span><cite>
Al‐Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open‐label, multicenter, single‐arm phase 3b expanded‐access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065‐1073. doi: 10.3324/HAEMATOL.2016.143677

</cite> [<a href="https://doi.org/10.3324/HAEMATOL.2016.143677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5060023/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27247324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Safety%20and%20efficacy%20of%20ruxolitinib%20in%20an%20open%E2%80%90label,%20multicenter,%20single%E2%80%90arm%20phase%203b%20expanded%E2%80%90access%20study%20in%20patients%20with%20myelofibrosis:%20a%20snapshot%20of%201144%20patients%20in%20the%20JUMP%20trial&amp;author=HK%20Al%E2%80%90Ali&amp;author=M%20Griesshammer&amp;author=P%20le%20Coutre&amp;volume=101&amp;issue=9&amp;publication_year=2016&amp;pages=1065-1073&amp;pmid=27247324&amp;doi=10.3324/HAEMATOL.2016.143677&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0003">
<span class="label">3.</span><cite>
Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243‐1252. doi: 10.1002/CNCR.32664

</cite> [<a href="https://doi.org/10.1002/CNCR.32664" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31860137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Life%20after%20ruxolitinib:%20reasons%20for%20discontinuation,%20impact%20of%20disease%20phase,%20and%20outcomes%20in%20218%20patients%20with%20myelofibrosis&amp;author=F%20Palandri&amp;author=M%20Breccia&amp;author=M%20Bonifacio&amp;volume=126&amp;issue=6&amp;publication_year=2020&amp;pages=1243-1252&amp;pmid=31860137&amp;doi=10.1002/CNCR.32664&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0004">
<span class="label">4.</span><cite>
Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase‐2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA‐2): a single‐arm, open‐label, non‐randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317‐e324. doi: 10.1016/S2352-3026(17)30088-1

</cite> [<a href="https://doi.org/10.1016/S2352-3026(17)30088-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8207822/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28602585/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Janus%20kinase%E2%80%902%20inhibitor%20fedratinib%20in%20patients%20with%20myelofibrosis%20previously%20treated%20with%20ruxolitinib%20(JAKARTA%E2%80%902):%20a%20single%E2%80%90arm,%20open%E2%80%90label,%20non%E2%80%90randomised,%20phase%202,%20multicentre%20study&amp;author=CN%20Harrison&amp;author=N%20Schaap&amp;author=AM%20Vannucchi&amp;volume=4&amp;issue=7&amp;publication_year=2017&amp;pages=e317-e324&amp;pmid=28602585&amp;doi=10.1016/S2352-3026(17)30088-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0005">
<span class="label">5.</span><cite>
Mascarenhas J. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol. 2022;15(8):671‐684. doi: 10.1080/17474086.2022.2112565

</cite> [<a href="https://doi.org/10.1080/17474086.2022.2112565" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35983661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Hematol&amp;title=Pacritinib%20for%20the%20treatment%20of%20patients%20with%20myelofibrosis%20and%20thrombocytopenia&amp;author=J%20Mascarenhas&amp;volume=15&amp;issue=8&amp;publication_year=2022&amp;pages=671-684&amp;pmid=35983661&amp;doi=10.1080/17474086.2022.2112565&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0006">
<span class="label">6.</span><cite>
Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY‐1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor‐naïve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844‐3850. doi: 10.1200/JCO.2017.73.4418

</cite> [<a href="https://doi.org/10.1200/JCO.2017.73.4418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6553796/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28930494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=SIMPLIFY%E2%80%901:%20a%20phase%20III%20randomized%20trial%20of%20momelotinib%20versus%20ruxolitinib%20in%20Janus%20kinase%20inhibitor%E2%80%90na%C3%AFve%20patients%20with%20myelofibrosis&amp;author=RA%20Mesa&amp;author=JJ%20Kiladjian&amp;author=JV%20Catalano&amp;volume=35&amp;issue=34&amp;publication_year=2017&amp;pages=3844-3850&amp;pmid=28930494&amp;doi=10.1200/JCO.2017.73.4418&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0007">
<span class="label">7.</span><cite>
Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open‐label, phase 3 trial. Lancet Haematol. 2018;5(2):e73‐e81. doi: 10.1016/S2352-3026(17)30237-5

</cite> [<a href="https://doi.org/10.1016/S2352-3026(17)30237-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29275119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Momelotinib%20versus%20best%20available%20therapy%20in%20patients%20with%20myelofibrosis%20previously%20treated%20with%20ruxolitinib%20(SIMPLIFY%202):%20a%20randomised,%20open%E2%80%90label,%20phase%203%20trial&amp;author=CN%20Harrison&amp;author=AM%20Vannucchi&amp;author=U%20Platzbecker&amp;volume=5&amp;issue=2&amp;publication_year=2018&amp;pages=e73-e81&amp;pmid=29275119&amp;doi=10.1016/S2352-3026(17)30237-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0008">
<span class="label">8.</span><cite>
Devlin R, Gupta V. Myelofibrosis: to transplant or not to transplant?
Hematology. 2016;2016(1):543‐551. doi: 10.1182/ASHEDUCATION-2016.1.543

</cite> [<a href="https://doi.org/10.1182/ASHEDUCATION-2016.1.543" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6142493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27913527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematology&amp;title=Myelofibrosis:%20to%20transplant%20or%20not%20to%20transplant?&amp;author=R%20Devlin&amp;author=V%20Gupta&amp;volume=2016&amp;issue=1&amp;publication_year=2016&amp;pages=543-551&amp;pmid=27913527&amp;doi=10.1182/ASHEDUCATION-2016.1.543&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0009">
<span class="label">9.</span><cite>
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895‐2901. doi: 10.1182/BLOOD-2008-07-170449

</cite> [<a href="https://doi.org/10.1182/BLOOD-2008-07-170449" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18988864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=New%20prognostic%20scoring%20system%20for%20primary%20myelofibrosis%20based%20on%20a%20study%20of%20the%20International%20Working%20Group%20for%20Myelofibrosis%20Research%20and%20Treatment&amp;author=F%20Cervantes&amp;author=B%20Dupriez&amp;author=A%20Pereira&amp;volume=113&amp;issue=13&amp;publication_year=2009&amp;pages=2895-2901&amp;pmid=18988864&amp;doi=10.1182/BLOOD-2008-07-170449&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0010">
<span class="label">10.</span><cite>
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703‐1708. doi: 10.1182/BLOOD-2009-09-245837

</cite> [<a href="https://doi.org/10.1182/BLOOD-2009-09-245837" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20008785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20dynamic%20prognostic%20model%20to%20predict%20survival%20in%20primary%20myelofibrosis:%20a%20study%20by%20the%20IWG%E2%80%90MRT%20(International%20Working%20Group%20for%20Myeloproliferative%20Neoplasms%20Research%20and%20Treatment)&amp;author=F%20Passamonti&amp;author=F%20Cervantes&amp;author=AM%20Vannucchi&amp;volume=115&amp;issue=9&amp;publication_year=2010&amp;pages=1703-1708&amp;pmid=20008785&amp;doi=10.1182/BLOOD-2009-09-245837&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0011">
<span class="label">11.</span><cite>
Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392‐397. doi: 10.1200/JCO.2010.32.2446

</cite> [<a href="https://doi.org/10.1200/JCO.2010.32.2446" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21149668/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=DIPSS%20plus:%20a%20refined%20Dynamic%20International%20Prognostic%20Scoring%20System%20for%20primary%20myelofibrosis%20that%20incorporates%20prognostic%20information%20from%20karyotype,%20platelet%20count,%20and%20transfusion%20status&amp;author=N%20Gangat&amp;author=D%20Caramazza&amp;author=R%20Vaidya&amp;volume=29&amp;issue=4&amp;publication_year=2011&amp;pages=392-397&amp;pmid=21149668&amp;doi=10.1200/JCO.2010.32.2446&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0012">
<span class="label">12.</span><cite>
Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype‐enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769‐1770. doi: 10.1200/JCO.2018.78.9867

</cite> [<a href="https://doi.org/10.1200/JCO.2018.78.9867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29708808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=MIPSS70+%20version%202.0:%20mutation%20and%20karyotype%E2%80%90enhanced%20international%20prognostic%20scoring%20system%20for%20primary%20myelofibrosis&amp;author=A%20Tefferi&amp;author=P%20Guglielmelli&amp;author=TL%20Lasho&amp;volume=36&amp;issue=17&amp;publication_year=2018&amp;pages=1769-1770&amp;pmid=29708808&amp;doi=10.1200/JCO.2018.78.9867&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0013">
<span class="label">13.</span><cite>
Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation‐enhanced international prognostic score system for transplantation‐age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310‐318. doi: 10.1200/JCO.2017.76.4886

</cite> [<a href="https://doi.org/10.1200/JCO.2017.76.4886" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29226763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=MIPSS70:%20mutation%E2%80%90enhanced%20international%20prognostic%20score%20system%20for%20transplantation%E2%80%90age%20patients%20with%20primary%20myelofibrosis&amp;author=P%20Guglielmelli&amp;author=TL%20Lasho&amp;author=G%20Rotunno&amp;volume=36&amp;issue=4&amp;publication_year=2018&amp;pages=310-318&amp;pmid=29226763&amp;doi=10.1200/JCO.2017.76.4886&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0014">
<span class="label">14.</span><cite>
Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861‐1869. doi: 10.1038/leu.2013.119

</cite> [<a href="https://doi.org/10.1038/leu.2013.119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23619563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Mutations%20and%20prognosis%20in%20primary%20myelofibrosis&amp;author=AM%20Vannucchi&amp;author=TL%20Lasho&amp;author=P%20Guglielmelli&amp;volume=27&amp;issue=9&amp;publication_year=2013&amp;pages=1861-1869&amp;pmid=23619563&amp;doi=10.1038/leu.2013.119&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0015">
<span class="label">15.</span><cite>
Passamonti F, Giorgino T, Mora B, et al. A clinical‐molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726‐2731. doi: 10.1038/leu.2017.169

</cite> [<a href="https://doi.org/10.1038/leu.2017.169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28561069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=A%20clinical%E2%80%90molecular%20prognostic%20model%20to%20predict%20survival%20in%20patients%20with%20post%20polycythemia%20vera%20and%20post%20essential%20thrombocythemia%20myelofibrosis&amp;author=F%20Passamonti&amp;author=T%20Giorgino&amp;author=B%20Mora&amp;volume=31&amp;issue=12&amp;publication_year=2017&amp;pages=2726-2731&amp;pmid=28561069&amp;doi=10.1038/leu.2017.169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0016">
<span class="label">16.</span><cite>
Gagelmann N, Mora B, Branzanti F, et al. Personalized transplant decision making for myelofibrosis in the era of molecular genetics and JAK inhibition. Blood. 2024;144(suppl 1):245. doi: 10.1182/BLOOD-2024-210804
39023869
</cite> [<a href="https://doi.org/10.1182/BLOOD-2024-210804" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Personalized%20transplant%20decision%20making%20for%20myelofibrosis%20in%20the%20era%20of%20molecular%20genetics%20and%20JAK%20inhibition&amp;author=N%20Gagelmann&amp;author=B%20Mora&amp;author=F%20Branzanti&amp;volume=144&amp;issue=suppl%201&amp;publication_year=2024&amp;pages=245&amp;doi=10.1182/BLOOD-2024-210804&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0017">
<span class="label">17.</span><cite>
Maffioli M, Mora B, Ball S, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022;6(6):1855‐1864. doi: 10.1182/BLOODADVANCES.2021006889

</cite> [<a href="https://doi.org/10.1182/BLOODADVANCES.2021006889" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8941454/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35130339/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=A%20prognostic%20model%20to%20predict%20survival%20after%206%20months%20of%20ruxolitinib%20in%20patients%20with%20myelofibrosis&amp;author=M%20Maffioli&amp;author=B%20Mora&amp;author=S%20Ball&amp;volume=6&amp;issue=6&amp;publication_year=2022&amp;pages=1855-1864&amp;pmid=35130339&amp;doi=10.1182/BLOODADVANCES.2021006889&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0018">
<span class="label">18.</span><cite>
Scalzulli E, Ielo C, Luise C, et al. RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real‐life cohort. Blood Adv. 2022;6(15):4424‐4426. doi: 10.1182/BLOODADVANCES.2022008158

</cite> [<a href="https://doi.org/10.1182/BLOODADVANCES.2022008158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9636318/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35737865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=RR6%20prognostic%20model%20provides%20information%20about%20survival%20for%20myelofibrosis%20treated%20with%20ruxolitinib:%20validation%20in%20a%20real%E2%80%90life%20cohort&amp;author=E%20Scalzulli&amp;author=C%20Ielo&amp;author=C%20Luise&amp;volume=6&amp;issue=15&amp;publication_year=2022&amp;pages=4424-4426&amp;pmid=35737865&amp;doi=10.1182/BLOODADVANCES.2022008158&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0019">
<span class="label">19.</span><cite>
Duminuco A, Nardo A, Garibaldi B, et al. Prediction of survival and prognosis migration from gold‐standard scores in myelofibrosis patients treated with ruxolitinib applying the RR6 prognostic model in a monocentric real‐life setting. J Clin Med. 2022;11(24):7418. doi: 10.3390/JCM11247418

</cite> [<a href="https://doi.org/10.3390/JCM11247418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9783796/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36556033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=Prediction%20of%20survival%20and%20prognosis%20migration%20from%20gold%E2%80%90standard%20scores%20in%20myelofibrosis%20patients%20treated%20with%20ruxolitinib%20applying%20the%20RR6%20prognostic%20model%20in%20a%20monocentric%20real%E2%80%90life%20setting&amp;author=A%20Duminuco&amp;author=A%20Nardo&amp;author=B%20Garibaldi&amp;volume=11&amp;issue=24&amp;publication_year=2022&amp;pages=7418&amp;pmid=36556033&amp;doi=10.3390/JCM11247418&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0020">
<span class="label">20.</span><cite>
Palandri F, Elli EM, Morsia E, et al. Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: the RUX‐MF real‐world study. Cancer. 2024;130(24):4257‐4266. doi: 10.1002/CNCR.35489

</cite> [<a href="https://doi.org/10.1002/CNCR.35489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11585342/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39078647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Clinical%20outcomes%20of%20ruxolitinib%20treatment%20in%20595%20intermediate%E2%80%901%20risk%20patients%20with%20myelofibrosis:%20the%20RUX%E2%80%90MF%20real%E2%80%90world%20study&amp;author=F%20Palandri&amp;author=EM%20Elli&amp;author=E%20Morsia&amp;volume=130&amp;issue=24&amp;publication_year=2024&amp;pages=4257-4266&amp;pmid=39078647&amp;doi=10.1002/CNCR.35489&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0021">
<span class="label">21.</span><cite>
Palandri F, Tiribelli M, Benevolo G, et al. Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: results from an independent study. Hematol Oncol. 2018;36(1):285‐290. doi: 10.1002/HON.2429

</cite> [<a href="https://doi.org/10.1002/HON.2429" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28512865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol&amp;title=Efficacy%20and%20safety%20of%20ruxolitinib%20in%20intermediate%E2%80%901%20IPSS%20risk%20myelofibrosis%20patients:%20results%20from%20an%20independent%20study&amp;author=F%20Palandri&amp;author=M%20Tiribelli&amp;author=G%20Benevolo&amp;volume=36&amp;issue=1&amp;publication_year=2018&amp;pages=285-290&amp;pmid=28512865&amp;doi=10.1002/HON.2429&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0022">
<span class="label">22.</span><cite>
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391‐2405. doi: 10.1182/BLOOD-2016-03-643544

</cite> [<a href="https://doi.org/10.1182/BLOOD-2016-03-643544" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27069254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%202016%20revision%20to%20the%20World%20Health%20Organization%20classification%20of%20myeloid%20neoplasms%20and%20acute%20leukemia&amp;author=DA%20Arber&amp;author=A%20Orazi&amp;author=R%20Hasserjian&amp;volume=127&amp;issue=20&amp;publication_year=2016&amp;pages=2391-2405&amp;pmid=27069254&amp;doi=10.1182/BLOOD-2016-03-643544&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0023">
<span class="label">23.</span><cite>
Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group‐Myeloproliferative Neoplasms Research and Treatment (IWG‐MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395‐1398. doi: 10.1182/BLOOD-2013-03-488098

</cite> [<a href="https://doi.org/10.1182/BLOOD-2013-03-488098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4828070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23838352/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Revised%20response%20criteria%20for%20myelofibrosis:%20International%20Working%20Group%E2%80%90Myeloproliferative%20Neoplasms%20Research%20and%20Treatment%20(IWG%E2%80%90MRT)%20and%20European%20LeukemiaNet%20(ELN)%20consensus%20report&amp;author=A%20Tefferi&amp;author=F%20Cervantes&amp;author=R%20Mesa&amp;volume=122&amp;issue=8&amp;publication_year=2013&amp;pages=1395-1398&amp;pmid=23838352&amp;doi=10.1182/BLOOD-2013-03-488098&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0024">
<span class="label">24.</span><cite>
Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25(9):1193‐1202. doi: 10.1038/modpathol.2012.87

</cite> [<a href="https://doi.org/10.1038/modpathol.2012.87" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22627739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mod%20Pathol&amp;title=The%20European%20Consensus%20on%20grading%20of%20bone%20marrow%20fibrosis%20allows%20a%20better%20prognostication%20of%20patients%20with%20primary%20myelofibrosis&amp;author=U%20Gianelli&amp;author=C%20Vener&amp;author=A%20Bossi&amp;volume=25&amp;issue=9&amp;publication_year=2012&amp;pages=1193-1202&amp;pmid=22627739&amp;doi=10.1038/modpathol.2012.87&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0025">
<span class="label">25.</span><cite>
Cancer Institute N
. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Accessed June 20, 2024. <a href="https://www.meddra.org/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.meddra.org/</a>
</cite>
</li>
<li id="cncr70062-bib-0026">
<span class="label">26.</span><cite>
Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098‐4103. doi: 10.1200/JCO.2012.42.3863

</cite> [<a href="https://doi.org/10.1200/JCO.2012.42.3863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4872304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23071245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Myeloproliferative%20neoplasm%20(MPN)%20symptom%20assessment%20form%20total%20symptom%20score:%20prospective%20international%20assessment%20of%20an%20abbreviated%20symptom%20burden%20scoring%20system%20among%20patients%20with%20MPNs&amp;author=RM%20Emanuel&amp;author=AC%20Dueck&amp;author=HL%20Geyer&amp;volume=30&amp;issue=33&amp;publication_year=2012&amp;pages=4098-4103&amp;pmid=23071245&amp;doi=10.1200/JCO.2012.42.3863&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0027">
<span class="label">27.</span><cite>
Nicolosi M, Mudireddy M, Lasho TL, et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018;32(5):1254‐1258. doi: 10.1038/S41375-018-0028-X

</cite> [<a href="https://doi.org/10.1038/S41375-018-0028-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5940639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29568091/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Sex%20and%20degree%20of%20severity%20influence%20the%20prognostic%20impact%20of%20anemia%20in%20primary%20myelofibrosis:%20analysis%20based%20on%201109%20consecutive%20patients&amp;author=M%20Nicolosi&amp;author=M%20Mudireddy&amp;author=TL%20Lasho&amp;volume=32&amp;issue=5&amp;publication_year=2018&amp;pages=1254-1258&amp;pmid=29568091&amp;doi=10.1038/S41375-018-0028-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0028">
<span class="label">28.</span><cite>
Breccia M, Palandri F, Martelli M, et al. Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI). Cancer. 2025;131(7):e35801. doi: 10.1002/cncr.35801

</cite> [<a href="https://doi.org/10.1002/cncr.35801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11925231/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40111826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Dosing%20and%20clinical%20outcomes%20of%20ruxolitinib%20in%20patients%20with%20myelofibrosis%20in%20a%20real%E2%80%90world%20setting:%20Interim%20results%20of%20the%20Italian%20observational%20study%20(ROMEI)&amp;author=M%20Breccia&amp;author=F%20Palandri&amp;author=M%20Martelli&amp;volume=131&amp;issue=7&amp;publication_year=2025&amp;pages=e35801&amp;pmid=40111826&amp;doi=10.1002/cncr.35801&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0029">
<span class="label">29.</span><cite>
Kröger N, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic haematopoietic stem‐cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11(1):e62‐e74. doi: 10.1016/S2352-3026(23)00305-8

</cite> [<a href="https://doi.org/10.1016/S2352-3026(23)00305-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38061384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Indication%20and%20management%20of%20allogeneic%20haematopoietic%20stem%E2%80%90cell%20transplantation%20in%20myelofibrosis:%20updated%20recommendations%20by%20the%20EBMT/ELN%20International%20Working%20Group&amp;author=N%20Kr%C3%B6ger&amp;author=A%20Bacigalupo&amp;author=T%20Barbui&amp;volume=11&amp;issue=1&amp;publication_year=2024&amp;pages=e62-e74&amp;pmid=38061384&amp;doi=10.1016/S2352-3026(23)00305-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0030">
<span class="label">30.</span><cite>
Hu S, Yang X, Lu Y, et al. Comparing the efficacy and safety of ruxolitinib in patients with lower and higher risk myelofibrosis: a multi‐center, single‐arm, exploratory and prospective study. Blood. 2024;144(suppl 1):1786. doi: 10.1182/BLOOD-2024-205090
</cite> [<a href="https://doi.org/10.1182/BLOOD-2024-205090" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Comparing%20the%20efficacy%20and%20safety%20of%20ruxolitinib%20in%20patients%20with%20lower%20and%20higher%20risk%20myelofibrosis:%20a%20multi%E2%80%90center,%20single%E2%80%90arm,%20exploratory%20and%20prospective%20study&amp;author=S%20Hu&amp;author=X%20Yang&amp;author=Y%20Lu&amp;volume=144&amp;issue=suppl%201&amp;publication_year=2024&amp;pages=1786&amp;doi=10.1182/BLOOD-2024-205090&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0031">
<span class="label">31.</span><cite>
Palandri F, Al‐Ali HK, Guglielmelli P, Zuurman MW, Sarkar R, Gupta V. Benefit of early ruxolitinib initiation regardless of fibrosis grade in patients with primary myelofibrosis: a post hoc analysis of the single‐arm phase 3b JUMP study. Cancers (Basel). 2023;15(10):2859. doi: 10.3390/cancers15102859

</cite> [<a href="https://doi.org/10.3390/cancers15102859" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10216208/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37345196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Benefit%20of%20early%20ruxolitinib%20initiation%20regardless%20of%20fibrosis%20grade%20in%20patients%20with%20primary%20myelofibrosis:%20a%20post%20hoc%20analysis%20of%20the%20single%E2%80%90arm%20phase%203b%20JUMP%20study&amp;author=F%20Palandri&amp;author=HK%20Al%E2%80%90Ali&amp;author=P%20Guglielmelli&amp;author=MW%20Zuurman&amp;author=R%20Sarkar&amp;volume=15&amp;issue=10&amp;publication_year=2023&amp;pages=2859&amp;pmid=37345196&amp;doi=10.3390/cancers15102859&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0032">
<span class="label">32.</span><cite>
Verstovsek S, Kiladjian JJ, Vannucchi AM, et al. Early intervention in myelofibrosis and impact on outcomes: a pooled analysis of the COMFORT‐I and COMFORT‐II studies. Cancer. 2023;129(11):1681‐1690. doi: 10.1002/CNCR.34707

</cite> [<a href="https://doi.org/10.1002/CNCR.34707" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36840971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Early%20intervention%20in%20myelofibrosis%20and%20impact%20on%20outcomes:%20a%20pooled%20analysis%20of%20the%20COMFORT%E2%80%90I%20and%20COMFORT%E2%80%90II%20studies&amp;author=S%20Verstovsek&amp;author=JJ%20Kiladjian&amp;author=AM%20Vannucchi&amp;volume=129&amp;issue=11&amp;publication_year=2023&amp;pages=1681-1690&amp;pmid=36840971&amp;doi=10.1002/CNCR.34707&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0033">
<span class="label">33.</span><cite>
Verstovsek S, Gotlib J, Mesa RA, et al. Long‐term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT‐I and ‐II pooled analyses. J Hematol Oncol. 2017;10(1):156. doi: 10.1186/S13045-017-0527-7

</cite> [<a href="https://doi.org/10.1186/S13045-017-0527-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5622445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28962635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Long%E2%80%90term%20survival%20in%20patients%20treated%20with%20ruxolitinib%20for%20myelofibrosis:%20COMFORT%E2%80%90I%20and%20%E2%80%90II%20pooled%20analyses&amp;author=S%20Verstovsek&amp;author=J%20Gotlib&amp;author=RA%20Mesa&amp;volume=10&amp;issue=1&amp;publication_year=2017&amp;pages=156&amp;pmid=28962635&amp;doi=10.1186/S13045-017-0527-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0034">
<span class="label">34.</span><cite>
Palandri F, Breccia M, Mazzoni C, et al. Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome. Cancer. 2023;129(11):1704‐1713. doi: 10.1002/CNCR.34722

</cite> [<a href="https://doi.org/10.1002/CNCR.34722" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36932983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Ruxolitinib%20in%20cytopenic%20myelofibrosis:%20response,%20toxicity,%20drug%20discontinuation,%20and%20outcome&amp;author=F%20Palandri&amp;author=M%20Breccia&amp;author=C%20Mazzoni&amp;volume=129&amp;issue=11&amp;publication_year=2023&amp;pages=1704-1713&amp;pmid=36932983&amp;doi=10.1002/CNCR.34722&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0035">
<span class="label">35.</span><cite>
Breccia M, Celant S, Palandri F, et al. The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real‐world study on AIFA monitoring registries. Br J Haematol. 2024;206(1):172‐179. doi: 10.1111/BJH.19812

</cite> [<a href="https://doi.org/10.1111/BJH.19812" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39363576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Haematol&amp;title=The%20impact%20of%20starting%20dose%20on%20overall%20survival%20in%20myelofibrosis%20patients%20treated%20with%20ruxolitinib:%20a%20prospective%20real%E2%80%90world%20study%20on%20AIFA%20monitoring%20registries&amp;author=M%20Breccia&amp;author=S%20Celant&amp;author=F%20Palandri&amp;volume=206&amp;issue=1&amp;publication_year=2024&amp;pages=172-179&amp;pmid=39363576&amp;doi=10.1111/BJH.19812&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0036">
<span class="label">36.</span><cite>
Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023;64(6):1063‐1081. doi: 10.1080/10428194.2023.2196593

</cite> [<a href="https://doi.org/10.1080/10428194.2023.2196593" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37081809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Lymphoma&amp;title=Ten%20years%20after%20ruxolitinib%20approval%20for%20myelofibrosis:%20a%20review%20of%20clinical%20efficacy&amp;author=N%20Pemmaraju&amp;author=P%20Bose&amp;author=R%20Rampal&amp;author=AT%20Gerds&amp;author=A%20Fleischman&amp;volume=64&amp;issue=6&amp;publication_year=2023&amp;pages=1063-1081&amp;pmid=37081809&amp;doi=10.1080/10428194.2023.2196593&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0037">
<span class="label">37.</span><cite>
Rossetti JM, Choksi R, Suthar P, et al. An analysis of ruxolitinib dosing for myelofibrosis in real‐world practice. Blood. 2023;142(suppl 1):5186. doi: 10.1182/BLOOD-2023-179402
</cite> [<a href="https://doi.org/10.1182/BLOOD-2023-179402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=An%20analysis%20of%20ruxolitinib%20dosing%20for%20myelofibrosis%20in%20real%E2%80%90world%20practice&amp;author=JM%20Rossetti&amp;author=R%20Choksi&amp;author=P%20Suthar&amp;volume=142&amp;issue=suppl%201&amp;publication_year=2023&amp;pages=5186&amp;doi=10.1182/BLOOD-2023-179402&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0038">
<span class="label">38.</span><cite>
Talpaz M, Erickson‐Viitanen S, Hou K, Hamburg S, Baer MR. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open‐label phase 2 study. J Hematol Oncol. 2018;11(1):101. doi: 10.1186/S13045-018-0642-0

</cite> [<a href="https://doi.org/10.1186/S13045-018-0642-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6081850/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30086777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Evaluation%20of%20an%20alternative%20ruxolitinib%20dosing%20regimen%20in%20patients%20with%20myelofibrosis:%20an%20open%E2%80%90label%20phase%202%20study&amp;author=M%20Talpaz&amp;author=S%20Erickson%E2%80%90Viitanen&amp;author=K%20Hou&amp;author=S%20Hamburg&amp;author=MR%20Baer&amp;volume=11&amp;issue=1&amp;publication_year=2018&amp;pages=101&amp;pmid=30086777&amp;doi=10.1186/S13045-018-0642-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70062-bib-0039">
<span class="label">39.</span><cite>
Cervantes F, Ross DM, Radinoff A, et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. 2021;35(12):3455‐3465. doi: 10.1038/S41375-021-01261-X

</cite> [<a href="https://doi.org/10.1038/S41375-021-01261-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8632662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34017073/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Efficacy%20and%20safety%20of%20a%20novel%20dosing%20strategy%20for%20ruxolitinib%20in%20the%20treatment%20of%20patients%20with%20myelofibrosis%20and%20anemia:%20the%20REALISE%20phase%202%20study&amp;author=F%20Cervantes&amp;author=DM%20Ross&amp;author=A%20Radinoff&amp;volume=35&amp;issue=12&amp;publication_year=2021&amp;pages=3455-3465&amp;pmid=34017073&amp;doi=10.1038/S41375-021-01261-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>Supplementary Material</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12369922/bin/CNCR-131-e70062-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">CNCR-131-e70062-s001.docx</a><sup> (670.1KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available from the corresponding author on reasonable request to the corresponding author (<span>francesca.palandri@unibo.it</span>) at the following <a href="https://zenodo.org/records/14017637" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://zenodo.org/records/14017637</a>.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cancer are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/cncr.70062"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/CNCR-131-e70062.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (744.2 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12369922/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12369922/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369922%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369922/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12369922/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12369922/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40839414/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12369922/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40839414/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12369922/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12369922/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="gPmRwdWkCbkjpPmSWTUUQgoqNrxf1N1SVzzENtSbRcg4ExwYZyCF8rmKsJlEV60M">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
